Abstract: An oral dosage formulation having one or more active pharmaceutical ingredients (APIs) or pharmaceutically acceptable salts thereof, 27 wt % to 34 wt % of hydroxypropyl methyl cellulose, 25 wt % to 53 wt % of high-density microcrystalline cellulose having a particle size of 50 micrometers to 100 micrometers, and 6.5 wt % to 8 wt % of lactose monohydrate. A non-exhaustive list of APIs that may be used in the oral dosage formulation includes: hydralazine or a pharmaceutically acceptable salt thereof; naltrexone or a pharmaceutically acceptable salt thereof; prazosin or a pharmaceutically acceptable salt thereof; torsemide or a pharmaceutically acceptable salt thereof; and aldosterone receptor antagonist(s) (e.g., spironolactone or eplerenone) or a pharmaceutically acceptable salt thereof. The formulations are used to treat disorders, including, but not limited to, heart failure-associated sleep apnea, uncontrolled or resistant hypertension, Crohn's disease, and systemic inflammation.

Abstract: An oral dosage formulation having one or more active pharmaceutical ingredients (APIs) or pharmaceutically acceptable salts thereof, 27 wt % to 34 wt % of hydroxypropyl methyl cellulose, 25 wt % to 53 wt % of high-density microcrystalline cellulose having a particle size of 50 micrometers to 100 micrometers, and 6.5 wt % to 8 wt % of lactose monohydrate. A non-exhaustive list of APIs that may be used in the oral dosage formulation includes: hydralazine or a pharmaceutically acceptable salt thereof; naltrexone or a pharmaceutically acceptable salt thereof; prazosin or a pharmaceutically acceptable salt thereof; torsemide or a pharmaceutically acceptable salt thereof; and aldosterone receptor antagonist(s) (e.g., spironolactone or eplerenone) or a pharmaceutically acceptable salt thereof. The formulations are used to treat disorders, including, but not limited to, heart failure-associated sleep apnea, uncontrolled or resistant hypertension, Crohn's disease, and systemic inflammation.

Abstract: Disclosed herein are oral dose formulations of aldosterone receptor antagonists, such as eplerenone and spironolactone, for the treatment of heart failure with preserved ejection fraction and uncontrolled hypertension.

Abstract: Fast issuance and execution of a multi-width instruction across multiple slices in a parallel slice processor core is supported in part through the use of an early notification signal passed between issue logic associated with multiple slices handling that multi-width instruction coupled with an issuance of a different instruction by the originating issue logic for the early notification signal.

Abstract: A design system accesses at least one placement template for at least one structured soft block composed of a pre-defined set of cells with relative placement information for the pre-defined set of cells. The design system optimizes implementation of the at least one structured soft block by propagating constants while preserving relative placement structure of the pre-defined set of cells within each at least one structured soft block according to the respective at least one placement template accessed for the at least one structured soft block.

Abstract: Operation of a multi-slice processor that includes a plurality of execution slices and an instruction sequencing unit. Operation of such a multi-slice processor includes: receiving, at the instruction sequencing unit, a load instruction indicating load address data and a load data length; determining a previous store instruction in an issue queue such that store address data for the previous store instruction corresponds to the load address data, wherein the previous store instruction corresponds to a store data length; and generating, in dependence upon the store data length matching the load data length, an indication in the issue queue that indicates a dependency between the load instruction and the previous store instruction.

Abstract: Embodiments herein describe a reservation station (RS) in a processor that merges control data from multiple sources into a merged control data value. Before an instruction issues, the RS gathers and saves control data indicating how the instruction is to be executed. This control data may be saved in control registers. An instruction, however, can update many different types of status control bits in these registers. As such, the RS may store different types of control data for an instruction. Instead of the RS containing multiple registers and data paths for every type of control data, the embodiments herein describe merge logic in the RS that permits control data from different sources to be merged into a single control data value. Once the instruction is issued, the RS passes the merged control data value to an execution unit for processing.

Abstract: Disclosed herein are oral dose formulations of aldosterone receptor antagonists, such as eplerenone and spironolactone, for the treatment of heart failure with preserved ejection fraction and uncontrolled hypertension.

Abstract: A design system accesses at least one placement template for at least one structured soft block composed of a pre-defined set of cells with relative placement information for the pre-defined set of cells. The design system optimizes implementation of the at least one structured soft block by propagating constants while preserving relative placement structure of the pre-defined set of cells within each at least one structured soft block according to the respective at least one placement template accessed for the at least one structured soft block.

Abstract: Disclosed herein are treatments for diseases such as sleep apnea, hyperuricemia, autistic spectrum disorder (ASD) and other brain disorders using controlled-release (CR, e.g., extended-release (ER) or prolonged-release (PR)) oral dosage formulations comprising an effective amount of Torsemide.

Abstract: Disclosed herein are treatments for diseases such as hypertension, diabetes, and congestive heart failure using controlled-release (CR, e.g., extended-release (ER) or prolonged-release (PR)) oral dosage formulations comprising an effective amount of Torsemide.

Abstract: Methods and apparatus for transmitting data between execution slices of a multi-slice processor including receiving, by an execution slice, a broadcast message comprising an instruction tag (ITAG) for a producer instruction, a latency, and a source identifier; determining that an issue queue in the execution slice comprises an ITAG for a consumer instruction, wherein the consumer instruction depends on result data from the producer instruction; calculating a cycle countdown using the latency and the source identifier; determining that the cycle countdown has expired; and in response to determining that the cycle countdown has expired, reading the result data from the producer instruction.

Abstract: Disclosed herein are treatments for diseases such as hypertension, diabetes, and congestive heart failure using controlled-release (CR, e.g., extended-release (ER) or prolonged-release (PR)) oral dosage formulations comprising an effective amount of Torsemide.

Abstract: Fast issuance and execution of a multi-width instruction across multiple slices in a parallel slice processor core is supported in part through the use of an early notification signal passed between issue logic associated with multiple slices handling that multi-width instruction coupled with an issuance of a different instruction by the originating issue logic for the early notification signal.

Abstract: Disclosed herein are controlled-release (GR, e.g., extended-release (ER) or prolonged-release (PR)) oral dosage formulation comprising an effective amount of Torsemide or a pharmaceutically acceptable salt thereof and at least one sustained release excipient comprising a polymer, wherein the at least one matrix component is selected from the group consisting of: hydroxy propyl cellulose (HPC), hydroxpropyl methyl cellulose (HPMC), glyceryl behenate, and a polyethylene glycol glyceride. Torsemide may be present in the formulation in a range of about 1 wt % to about 20 wt %, or about 5 wt % to about 10 wt % and the matrix component is present in the formulation in a range of about 5 wt % to about 50 wt %, or about 15 wt % to about 35 wt %. The formulation may further comprise at least one binder, lactose, talc and magnesium stearate. Methods of making and using the controlled-release oral dosage Torsemide formulation are also disclosed. A novel mechanism for Torsemide action in diuresis is further disclosed.

Abstract: Fast issuance and execution of a multi-width instruction across multiple slices in a parallel slice processor core is supported in part through the use of an early notification signal passed between issue logic associated with multiple slices handling that multi-width instruction coupled with an issuance of a different instruction by the originating issue logic for the early notification signal.

Abstract: Provided herein are methods of computer-assisted identification of a compound that binds to a target protein.

Abstract: Fast issuance and execution of a multi-width instruction across multiple slices in a parallel slice processor core is supported in part through the use of an early notification signal passed between issue logic associated with multiple slices handling that multi-width instruction coupled with an issuance of a different instruction by the originating issue logic for the early notification signal.

Abstract: Operation of a multi-slice processor that includes execution slices and a dispatch network of the multi-slice processor implementing a hardware level mechanism to overcome a system hang. Such a multi-slice processor includes a plurality of execution slices and a dispatch network of the multi-slice processor implementing a hardware level mechanism to overcome a system hang. Operation of such a multi-slice processor includes, storing, in one or more logical units of a plurality of logical units of an age array, a logical value representing a relative age between instructions; propagating, in response to a current instruction being in a hang state, a hang signal to the plurality of logical units of the age array; in response to the hang signal, generating, from the plurality of logical units, a plurality of logical output values indicating a next instruction ready for execution; and issuing the next instruction for execution.

Abstract: Disclosed herein are methods and systems for discovering and analyzing drug related side effects, which are also referred to herein as “off-target responses”. Side effects can be positive/beneficial side effects or negative/undesirable side effects. Further, the positive side effects can be utilize to repurpose a drug while undesirable side effects can be eliminated to make the drug(s) safer. Disclosed methods can utilize any one or more of a variety of data sources and data collection techniques to acquire data that can be utilized to identify side effects related to a particular drug and to determine that causal links between the drug, the patients, and the side effects.